Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05618600 · ClinicalTrials.gov registry record
Scripps-eMed Covid-19 Study: A Prospective Monitoring Study for Those Individuals Treated With Paxlovid
A clinical trial, sponsored by Scripps Translational Science Institute.
- Completed
- Registry status
- 917
- Enrollment target
NCT05618600: Completed study, sponsored by Scripps Translational Science Institute.
NCT05618600 is a clinical trial that has completed, run by Scripps Translational Science Institute. The registered enrollment target is 917 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05618600 has completed, sponsored by Scripps Translational Science Institute.
- COMPLETED
- Registry status
- 917 participants
- Enrollment target
Study Summary
A prospective monitoring study for those individuals treated with Paxlovid
Primary Outcome
Incidence of paxlovid rebound defined as test positivity after a documented negative rapid antigen test post 5 day course of Paxlovid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 917 participants |
| Start Date | 2022-08-04 |
| Est. Completion | 2024-06-10 |
What the finished NCT05618600 record still lists
NCT05618600 is an observational study that tracks outcomes without assigning an intervention. The registered 917 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT05618600 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05618600 about?
NCT05618600 is a clinical study titled "Scripps-eMed Covid-19 Study: A Prospective Monitoring Study for Those Individuals Treated With Paxlovid". A prospective monitoring study for those individuals treated with Paxlovid
What is the current status of trial NCT05618600?
This trial is currently completed. The enrollment target is 917 participants. The study started on 2022-08-04. Estimated completion is 2024-06-10.
Who is sponsoring clinical trial NCT05618600?
This trial is sponsored by Scripps Translational Science Institute, which has 41 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05739955 · 918 participants · NA
Impact of Enhanced Daily Disinfection on Environmental Contamination in Hospital Rooms
- NCT04589845 · 920 participants · Phase 2
Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study
- NCT06109870 · 920 participants · NA
Prevención en Sus Manos: Feasibility of a Novel Community-Based Strategy to Improve Access to Cervical Cancer Screening
- NCT06957366 · 920 participants · NA
Perioperative Anticoagulant Use for Surgery Evaluation -2 (PAUSE-2) Study Patients Receiving a Direct Oral Anticoagulant (DOACs-Dabigatran, Rivaroxaban, Apixaban or Edoxaban) and Needing Elective High-Bleed-Risk Surgery or an Invasive Procedure
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI